Zepbound Cost in 2026: Vials, Pens, Insurance and Medicare

Written by Nataliia Bondarchuk. Updated November 8, 2026.

As of November 2026, Zepbound costs between $25 and about $700 a month depending on how you pay: as little as $25 per fill with commercial insurance that covers it and Lilly's savings card, $299 to $449 a month paying cash for the KwikPen or vials if you refill on time, and $50 a month for eligible Medicare patients through the new GLP-1 Bridge. All of the Lilly prices in this guide are per Lilly's Zepbound coverage and savings page dated October 22, 2026, and the Medicare figures are per Medicare.gov's June 2026 Bridge publication. Zepbound (tirzepatide) is Eli Lilly's weekly injection for weight management and obstructive sleep apnea, sold as single-dose pens, vials and a multi-dose KwikPen. Prices change often, so confirm the current price with your pharmacy or LillyDirect, Lilly's own pharmacy service, before you fill. This guide covers each payment route, the 45-day refill rule, Medicare, Medicaid and employer coverage.

What you pay depends on your coverage, whether your plan covers Zepbound for your diagnosis, and which device you use. The table sets out the main routes as of November 2026, with the source and date of each figure. A "month" in Lilly's pricing is 28 days, which is four weekly doses.

Still deciding? Our tirzepatide vs semaglutide comparison covers results.

The KwikPen is a multi-dose pen that holds four weekly doses, so one device lasts a 28-day month. Lilly launched it for self-pay patients on LillyDirect on February 23, 2026, starting at $299 a month for the 2.5 mg dose, the same price as vials at the time. Per Lilly's page dated October 22, 2026, prices are below; the lower higher-dose price needs on-time refills. The KwikPen offer allows up to 11 fills a year and expires December 31, 2026.

Your dose usually starts at 2.5 mg and steps up every four weeks, so the monthly price rises as you move up; our guide to tirzepatide dosage for weight loss explains the schedule, and how the Zepbound KwikPen works covers the device itself. Fierce Pharma reported that commercially insured LillyDirect users can choose only single-dose pens.

Per Lilly's page dated October 22, 2026, self-pay pricing "starts at $299 for a KwikPen or 4 vials," which is the 2.5 mg starting price. Lilly's page does not list a separate price for each vial strength, and we could not confirm current per-dose vial prices on a Lilly page, so we have not listed them here. For history, Lilly's December 1, 2025 vial price cut set $299, $399 and $449 (7.5 to 15 mg), down from $599 to $1,049 for the higher doses. If you plan to use vials, ask LillyDirect for the current price of your exact strength before ordering.

The 45-day rule is the detail most likely to raise your bill. Per Lilly's page dated October 22, 2026, the $449 price for the 7.5 mg to 15 mg KwikPen holds only if you refill within 45 days of your previous delivery. If you go longer than 45 days between fills, the price returns to the regular $499 for 7.5 mg or $699 for 10 mg, 12.5 mg and 15 mg. At the highest doses that is a $250 difference for one month.

Gaps happen through travel, missed reminders or pauses for side effects. The 2.5 mg and 5 mg prices are the same either way. Set a reorder reminder about three weeks after each delivery, and ask LillyDirect how it counts the 45 days. Thinking of a break? Read what happens when you stop tirzepatide first.

The list price, sometimes called the wholesale acquisition cost, is the price before insurance, rebates or savings programs. We could not confirm it on a Lilly-owned page. Secondary reports put it at about $1,086 a month for the single-dose pen: news coverage of the November 2025 federal pricing deal described a drop "from $1,086," and a weight-loss program's March 2026 summary gave $1,086.37. Treat that figure as approximate. Few people pay it, but it can matter if you pay coinsurance or have a high deductible.

Lilly's savings card, per its page dated October 22, 2026, works in two different ways depending on whether your commercial plan covers Zepbound. It expires December 31, 2026, and Lilly could change the terms for 2027.

If your plan's share is high, the $1,300 yearly cap can run out before December, and your cost then rises.

Yes, in some cases. Per Medicare.gov's June 2026 publication, the Medicare GLP-1 Bridge started July 1, 2026. It lets eligible people with Part D drug coverage get Zepbound for $50 a month regardless of income. NPR reported on May 6, 2026 that the Bridge was extended to run through December 31, 2027. Key details:

People with moderate to severe obstructive sleep apnea are excluded from the Bridge, per Medicare.gov's June 2026 publication, and so are people with type 2 diabetes or fatty liver disease. They go through their regular Part D plan, which may cover Zepbound for sleep apnea, an FDA-approved use. NPR reported that these patients "pay that plan's price, which may be higher than $50." Check your plan's drug list before filling.

In November 2025, Lilly and Novo Nordisk struck pricing deals with the federal government. Pharmacy Times reported on November 6, 2025 that tirzepatide would be offered on TrumpRx at "an average of $346," with a Medicare and Medicaid price of $245 and a $50 Medicare copay. TrumpRx.gov launched around February 5, 2026, listing Zepbound "starting at $299," per the Washington Times on February 6, 2026. The site sends you to the manufacturer's own site or a coupon, so prices generally match Lilly's self-pay prices. Purchases made this way generally do not count toward your insurance deductible. We could not confirm the current per-dose price shown on TrumpRx, so compare it with LillyDirect on the day you buy.

It depends on your state. KFF reported on January 16, 2026 that 13 state Medicaid programs covered GLP-1 drugs for obesity as of January 2026, down from 16. California, New Hampshire, Pennsylvania and South Carolina ended that coverage. Medicaid members cannot use Lilly's savings card, so ask your state plan whether Zepbound is covered and what prior authorization it needs.

The picture is mixed. CVS Caremark, a large pharmacy benefit manager, announced on May 28, 2026 that Zepbound would return as a preferred drug on its most common commercial template formularies on October 1, 2026, although each employer or plan sponsor can customize its coverage. Lilly's October 22, 2026 page says that coverage starts "at $25/month," but this is not guaranteed and CVS did not publish copay amounts. But KFF Health News reported on September 8, 2026 that, according to the Business Group on Health, 60% of large employers cover GLP-1 drugs, down from 72%. Ask your benefits team whether your plan covers Zepbound and needs prior authorization. If your plan covers Mounjaro but not Zepbound, note that Mounjaro is the same drug approved for type 2 diabetes, and coverage depends on your diagnosis.

There is no FDA-approved generic Zepbound as of November 2026. Our guide to generic Zepbound explains why and what to watch for. Compounded tirzepatide is not FDA-approved and its quality is not checked like the brand product; we do not give dosing for it. The lowest legitimate prices are the routes above. Staying on a lower dose that works for you, such as tirzepatide 5 mg, can also keep your monthly cost down, but dose decisions belong to your doctor.

Zepbound can take several months to reach full effect, as explained in how long Zepbound takes to work, so plan for the cost over at least a year rather than a single month.

As of November 2026, Zepbound can cost as little as $25 per fill with insurance that covers it and Lilly's savings card, $299 to $449 a month as a self-pay KwikPen with on-time refills, and $50 a month through Medicare's GLP-1 Bridge for eligible people. Missing the 45-day refill window can raise higher-dose self-pay prices to $499 or $699, and people with sleep apnea on Medicare pay their Part D plan's price instead. Prices change, so confirm with your pharmacy or LillyDirect before you fill.

This article is general information, not financial or medical advice, and is not sponsored by Eli Lilly or any pharmacy. Prices and program terms were checked in November 2026 and change often; confirm current prices with your pharmacy, your insurer or LillyDirect.